Trials / Unknown
UnknownNCT03416699
Chinese TaTME Registry Collaborative
Chinese Transanal Total Mesorectal Excision Registry Collaborative: A Nationwide Registry Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Total mesorectal excision (TME) is the gold standard procedure for treating rectal cancer. However, in patients with obesity, prostate hypertrophy, low located tumor or/and pelvic stenosis, the traditional laparoscopic or open surgery is not easy to conduct. Transanal total mesorectal excision (TaTME) might serve as a better procedure for these patients, for it might ease the dissection of the low mesorectum. So far, several studies have showed the promising results of TaTME, but the multi-center data in China is still lacking. This nationwide registry study included more than 30 Chinese hospitals, aiming at obtaining data on the safety and efficacy of this procedure in Chinese patients with rectal cancer and encouraging future research in this field.
Conditions
Timeline
- Start date
- 2017-11-15
- Primary completion
- 2018-11-15
- Completion
- 2021-11-15
- First posted
- 2018-01-31
- Last updated
- 2018-01-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03416699. Inclusion in this directory is not an endorsement.